September 16, 2024 09:00 AM EDTUpdated 09:24 AM

Merck's Eliav Barr on subcutaneous Keytruda, Summit and deal shopping

Kyle LaHucik

Senior Reporter

BARCELONA — In the span of 30 minutes, 29-year Merck veteran Eliav Barr can analogize drug development dealmaking to Reese’s candy, call himself an “old …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck's Eliav Barr on subcutaneous Keytruda, Summit and deal shopping

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Avid Bioservices to be sold to private equity firms for $1.1B

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Denali teases early data for enzyme replacement therapy in rare disease

Genmab chops early cancer prospects to prioritize Phase 3 projects

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Mer­ck­'s Eli­av Barr on sub­cu­ta­neous Keytru­da, Sum­mit and deal shop­ping

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

De­nali teas­es ear­ly da­ta for en­zyme re­place­ment ther­a­py in rare dis­ease

Gen­mab chops ear­ly can­cer prospects to pri­or­i­tize Phase 3 projects

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Merck's Eliav Barr on subcutaneous Keytruda, Summit and deal shopping

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Avid Bioservices to be sold to private equity firms for $1.1B

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Denali teases early data for enzyme replacement therapy in rare disease

Genmab chops early cancer prospects to prioritize Phase 3 projects

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks